ALLOSTERIC TRANS-SPLICING GROUP I RIBOZYME WHOSE ACTIVITY OF TARGET-SPECIFIC RNA REPLACEMENT IS CONTROLLED BY THEOPHYLLINE
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Jan 6, 2011
app pub date -
Dec 16, 2008
filing date -
Mar 27, 2008
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Provided is an allosteric trans-splicing group I ribozyme whose target-specific RNA replacement activity is controlled by theophylline, wherein the hTERT-targeting trans-splicing ribozyme recognizes mRNA of human telomerase reverse transcriptase (hTERT) as a cancer-specific RNA transcript to bind a theophylline aptamer to an hTERT target trans-splicing ribozyme via a communication module, the hTERT target trans-splicing ribozyme having a verified trans-splicing ability. The allosteric trans-splicing group I ribozyme may be useful to selectively diagnose only cancer cells that express target hTERT RNA, or induce their apoptosis since the activity of the allosteric trans-splicing group I ribozyme is dependently controlled by theophylline to correct target hTERT RNA by the trans-splicing reaction.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully